Safety and Efficacy of Favipiravir for the management of COVID-19 Patients: A Randomized Control Trial

DOI record: { "DOI": "10.1016/j.clinpr.2022.100145", "ISSN": [ "2590-1702" ], "URL": "http://dx.doi.org/10.1016/j.clinpr.2022.100145", "alternative-id": [ "S2590170222000139" ], "article-number": "100145", "author": [ { "affiliation": [], "family": "Rahman", "given": "S.M. Abdur", "sequence": "first" }, { "affiliation": [], "family": "Kabir", "given": "Ahmedul", "sequence": "additional" }, { "affiliation": [], "family": "Abdullah", "given": "ABM", "sequence": "additional" }, { "affiliation": [], "family": "Billal Alam", "given": "Md", "sequence": "additional" }, { "affiliation": [], "family": "Azad", "given": "Khan Abul Kalam", "sequence": "additional" }, { "affiliation": [], "family": "Titu Miah", "given": "Md", "sequence": "additional" }, { "affiliation": [], "family": "Mowla", "given": "Syed Ghulam Mogni", "sequence": "additional" }, { "affiliation": [], "family": "Deb", "given": "Sudip Ranjan", "sequence": "additional" }, { "affiliation": [], "family": "Amin", "given": "Mohammad Robed", "sequence": "additional" }, { "affiliation": [], "family": "Asaduzzaman", "given": "Muhammad", "sequence": "additional" } ], "container-title": "Clinical Infection in Practice", "container-title-short": "Clinical Infection in Practice", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 5, 12 ] ], "date-time": "2022-05-12T03:11:37Z", "timestamp": 1652325097000 }, "deposited": { "date-parts": [ [ 2022, 5, 12 ] ], "date-time": "2022-05-12T03:11:54Z", "timestamp": 1652325114000 }, "indexed": { "date-parts": [ [ 2022, 5, 12 ] ], "date-time": "2022-05-12T03:40:55Z", "timestamp": 1652326855425 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2022, 5 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 5, 1 ] ], "date-time": "2022-05-01T00:00:00Z", "timestamp": 1651363200000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 4, 22 ] ], "date-time": "2022-04-22T00:00:00Z", "timestamp": 1650585600000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S2590170222000139?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S2590170222000139?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "100145", "prefix": "10.1016", "published": { "date-parts": [ [ 2022, 5 ] ] }, "published-print": { "date-parts": [ [ 2022, 5 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1002/jmv.25678", "article-title": "Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle", "author": "Lu", "doi-asserted-by": "crossref", "first-page": "401", "issue": "4", "journal-title": "J Med Virol.", "key": "10.1016/j.clinpr.2022.100145_b0005", "volume": "92", "year": "2020" }, { "DOI": "10.1001/jama.2020.1585", "article-title": "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "1061", "issue": "11", "journal-title": "JAMA", "key": "10.1016/j.clinpr.2022.100145_b0010", "volume": "323", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30183-5", "article-title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan", "author": "Huang", "doi-asserted-by": "crossref", "first-page": "497", "issue": "10223", "journal-title": "China. Lancet", "key": "10.1016/j.clinpr.2022.100145_b0015", "volume": "395", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30566-3", "article-title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "1054", "issue": "10229", "journal-title": "Lancet", "key": "10.1016/j.clinpr.2022.100145_b0020", "volume": "395", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30633-4", "article-title": "Clinical course and mortality risk of severe COVID-19", "author": "Weiss", "doi-asserted-by": "crossref", "first-page": "1014", "issue": "10229", "journal-title": "Lancet", "key": "10.1016/j.clinpr.2022.100145_b0025", "volume": "395", "year": "2020" }, { "key": "10.1016/j.clinpr.2022.100145_b0030", "unstructured": "Worldometer: https://www.worldometers.info/coronavirus/. Accessed 5th April, 2021." }, { "article-title": "WHO declares COVID-19 a pandemic", "author": "Cucinotta", "first-page": "157", "issue": "1", "journal-title": "Acta Biomed", "key": "10.1016/j.clinpr.2022.100145_b0035", "volume": "91", "year": "2020" }, { "DOI": "10.1177/10105395211014345", "article-title": "Major depressive and Generalized anxiety disorders among university students during the second wave of COVID-19 outbreak in Bnagladesh", "author": "Hossain", "doi-asserted-by": "crossref", "first-page": "676", "issue": "5", "journal-title": "Asia Pac. J. Pubic Health", "key": "10.1016/j.clinpr.2022.100145_b0040", "volume": "33", "year": "2021" }, { "DOI": "10.1016/j.ijsu.2020.04.018", "article-title": "The Socio-economic implications of the coronavirus pandemic (COVID-19): A review", "author": "Nicola", "doi-asserted-by": "crossref", "first-page": "185", "journal-title": "Int. J. Surg.", "key": "10.1016/j.clinpr.2022.100145_b0045", "volume": "78", "year": "2020" }, { "DOI": "10.3390/su12135343", "article-title": "Covid-19 and the UN Sustainable Development Goals: Threat to Solidarity or an Opportunity?", "author": "Leal Filho", "doi-asserted-by": "crossref", "first-page": "5343", "issue": "13", "journal-title": "Sustainability", "key": "10.1016/j.clinpr.2022.100145_b0050", "volume": "12", "year": "2020" }, { "DOI": "10.1080/14787210.2021.1864327", "article-title": "Repurposing therapeutic agents againsts SARS-CoV-2 infection: most promising and neoteric progress", "author": "Hossain", "doi-asserted-by": "crossref", "first-page": "1009", "issue": "8", "journal-title": "Expert Rev Antiinfective Therapy.", "key": "10.1016/j.clinpr.2022.100145_b0055", "volume": "19", "year": "2021" }, { "DOI": "10.3389/fphar.2021.659577", "article-title": "Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021", "author": "Alam", "doi-asserted-by": "crossref", "journal-title": "Front Pharmacol.", "key": "10.1016/j.clinpr.2022.100145_b0060", "volume": "12", "year": "2021" }, { "DOI": "10.1038/d41573-020-00016-0", "article-title": "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)", "author": "Li", "doi-asserted-by": "crossref", "first-page": "149", "issue": "3", "journal-title": "Nat Rev Drug Discov.", "key": "10.1016/j.clinpr.2022.100145_b0065", "volume": "19", "year": "2020" }, { "key": "10.1016/j.clinpr.2022.100145_b0070", "unstructured": "NIH US. National Library of Medicine ClinicalTrial.gov. https://clinicaltrials.gov/ct2/home.Accessed September 5, 2020." }, { "DOI": "10.1016/j.antiviral.2013.09.015", "article-title": "Favipiravir (T-705), a novel viral RNA polymerase inhibitor", "author": "Furuta", "doi-asserted-by": "crossref", "first-page": "446", "issue": "2", "journal-title": "Antiviral Res.", "key": "10.1016/j.clinpr.2022.100145_b0075", "volume": "100", "year": "2013" }, { "DOI": "10.1017/dmp.2014.151", "article-title": "Favipiravir: a new medication for the ebola virus disease pandemic", "author": "Nagata", "doi-asserted-by": "crossref", "first-page": "79", "issue": "1", "journal-title": "Disaster Medicine and Public Health preparedness", "key": "10.1016/j.clinpr.2022.100145_b0080", "volume": "9", "year": "2015" }, { "DOI": "10.1016/j.antiviral.2018.03.003", "article-title": "Favipiravir as a potential countermeasure against neglected and emerging RNA viruses", "author": "Delang", "doi-asserted-by": "crossref", "first-page": "85", "journal-title": "Antiviral Res.", "key": "10.1016/j.clinpr.2022.100145_b0085", "volume": "153", "year": "2018" }, { "DOI": "10.1128/AAC.01739-09", "article-title": "In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 a (H1N1) viruses", "author": "Sleeman", "doi-asserted-by": "crossref", "first-page": "2517", "issue": "6", "journal-title": "Antimicrob Agents Chemother.", "key": "10.1016/j.clinpr.2022.100145_b0090", "volume": "54", "year": "2010" }, { "DOI": "10.1038/s41422-020-0282-0", "article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019nCoV) in vitro", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "269", "issue": "3", "journal-title": "Cell Res", "key": "10.1016/j.clinpr.2022.100145_b0095", "volume": "30", "year": "2020" }, { "article-title": "Experimental treatment with favipiravir for COVID-19: An open-label control study", "author": "Cai", "journal-title": "Engineering (Beijing)", "key": "10.1016/j.clinpr.2022.100145_b0100", "year": "2020" }, { "key": "10.1016/j.clinpr.2022.100145_b0105", "unstructured": "Roser M, et.al. Coronavirus Disease (COVID-19)-Statistics and Research. Published online at OurworldData.org. retrieved from https://ourworldindata.org/coronavirus. Accessed 8 Sep 2020." }, { "DOI": "10.3389/fimmu.2020.01991", "article-title": "The impact of Pre-existing comorbidities and Therapeutic Interventions on COVID-19", "author": "Callender", "doi-asserted-by": "crossref", "journal-title": "Front. Immunol.", "key": "10.1016/j.clinpr.2022.100145_b0110", "volume": "11", "year": "2020" }, { "key": "10.1016/j.clinpr.2022.100145_b0115", "unstructured": "Pharmaceuticals and Medical Devices Agency, Report on the deliberation results – avigan. Japan; Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, 2011. Available at: www.pmda.go.jp/files/000210319.pdf. Accessed September 20, 2020." }, { "key": "10.1016/j.clinpr.2022.100145_b0120", "unstructured": "COVID-19: Glenmark’s favipiravir shows encouraging results in phase 3 clinical trial. The Indian Express. https://www.newindianexpress.com/nation/2020/jul/23/covid-19-glenmarks-favipiravir-shows-encouraging-results-in-phase-3-clinical-trial-2173500.html. Accessed Septembe 23r, 2020." }, { "article-title": "Favipiravir versus arbidol for COVID-19: A randomized clinical trial", "author": "Chen", "journal-title": "medRxiv.", "key": "10.1016/j.clinpr.2022.100145_b0125", "year": "2020" }, { "key": "10.1016/j.clinpr.2022.100145_b0130", "unstructured": "Trial site news. Russia ministry of health approves avifavir (favipiravir) for COVID-19 patients—cuts duration of illness by over 50 %. https://www.trialsitenews.com/russia-ministry-of-health-approves-avifavir-favipiravir-for-covid-19-patients-cuts-duration-of-illness-by-over-50/. Accessed September 1, 2020)." }, { "DOI": "10.1038/s41598-021-90551-6", "article-title": "The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials", "author": "Hassanipour", "doi-asserted-by": "crossref", "issue": "1", "journal-title": "Scientific reports.", "key": "10.1016/j.clinpr.2022.100145_b0135", "volume": "11", "year": "2021" }, { "DOI": "10.2183/pjab.93.027", "article-title": "Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase", "author": "Furuta", "doi-asserted-by": "crossref", "first-page": "449", "issue": "7", "journal-title": "Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.", "key": "10.1016/j.clinpr.2022.100145_b0140", "volume": "93", "year": "2017" }, { "DOI": "10.1016/S2055-6640(20)30016-9", "article-title": "A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic?", "author": "Pilkington", "doi-asserted-by": "crossref", "first-page": "45", "issue": "2", "journal-title": "J. Virus Erad.", "key": "10.1016/j.clinpr.2022.100145_b0145", "volume": "6", "year": "2020" }, { "DOI": "10.1002/cpt.1844", "article-title": "Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection", "author": "Du", "doi-asserted-by": "crossref", "first-page": "242", "issue": "2", "journal-title": "Clinical Pharmacology and Therapeutics", "key": "10.1016/j.clinpr.2022.100145_b0150", "volume": "108", "year": "2020" } ], "reference-count": 30, "references-count": 30, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S2590170222000139" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "General Medicine" ], "subtitle": [], "title": "Safety and Efficacy of Favipiravir for the management of COVID-19 Patients: A Randomized Control Trial", "type": "journal-article" }